Trial reportEuropean journal of cancer (Oxford, England : 1990)2014
The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
Trial report in European journal of cancer (Oxford, England : 1990), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis.Breast cancer research and treatment · 2022Pooled it
- Challenges and barriers for the adoption of personalized medicine in Europe: the case of Oncotype DX Breast Recurrence ScoreDiagnosis (Berlin, Germany) · 2025Review
- Post-diagnosis weight trajectories and mortality among women with breast cancer.NPJ breast cancer · 2023Article
- Review
- Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.Nature communications · 2023Article
- Clinicopathological Factors Affecting Breast Cancer Survival in Jamaican Women: A Retrospective Review.Journal of racial and ethnic health disparities · 2023Article
- Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer.Breast (Edinburgh, Scotland) · 2022Article
- Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements.The EPMA journal · 2022Review
- Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.International journal of molecular sciences · 2022Article
- A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©.Journal of personalized medicine · 2022Article
- Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry.Scientific reports · 2022Article
- 6q deletion is frequent but unrelated to patient prognosis in breast cancer.Breast cancer (Tokyo, Japan) · 2022Article
- 'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.Frontiers in molecular biosciences · 2022Review
- Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures.BioMed research international · 2022Review
- Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score.Contemporary oncology (Poznan, Poland) · 2022Article
- AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study.Frontiers in oncology · 2022Article
- Explainable artificial intelligence for precision medicine in acute myeloid leukemia.Frontiers in immunology · 2022Article
- High mitochondrial content is associated with breast cancer aggressiveness.Molecular and clinical oncology · 2021Article
- Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use.Breast cancer research : BCR · 2021Article
- Precision Medicine: Making It Happen for Malaysia.The Malaysian journal of medical sciences : MJMS · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe use of chemotherapy in node-negative, (O)Estrogen Receptor (ER)-positive breast cancer has changed significantly since the introduction of Oncotype DX to determine systemic recurrence risk based on tumour genomic signature.
aimsThis study aims to
methodsA cohort study was undertaken, including consecutive patients with early node-negative, ER-positive breast cancer diagnosed between 2006 and May 2013, including a period of prospective clinical trial (Trial Assigning Individualised Options for Treatment (TAILORx)) recruitment. Data were collected regarding patient demographics, tumour clinico-pathological features, Oncotype DX use and recurrence score and chemotherapy use. All therapeutic decisions were made following multidisciplinary discussion, with adherence to guidelines and consideration of trial protocol and Oncotype DX recurrence scores.
results479 consecutive patients were included in the study, of whom 241 (50%) underwent Oncotype DX testing, 97 as part of the TAILORx clinical trial. Oncotype DX testing began on a trial basis in 2007 and until October 2011, only patients enrolled on TAILORx availed of genomic profiling. From October 2011, Oncotype DX was used in all eligible patients as per National Cancer Control Programme (NCCP) guidelines. A total of 216 (45%) patients received chemotherapy. The use of chemotherapy changed in inverse proportion to the availability of the genomic assay. Of those patients in whom Oncotype DX was utilised, 138 (57%) were spared chemotherapy.
conclusionThis study validates the use of molecular testing in the rationalisation of systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.